medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2005; 4 (3)


Current concepts in the management and treatment of hepatitis C in HIV-infected patients

Núñez M, Soriano V

Idioma: Ingles.
Referencias bibliográficas: 92
Paginas: 151-160
Archivo PDF: 97.59 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492-7.

  2. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-14.

  3. Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-72.

  4. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-9.

  5. Gebo K, Diener-West M, Moore R. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34: 165-73.

  6. Reisler R, Han C, Burman W, Tedaldi E, Neaton J. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34: 379-86.

  7. Murphy E, Collier A, Kalish L, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.

  8. Nuñez M, Soriano V. New hopes for HIV and HCV coinfection in 2004. HIV Clin Trials 2004; 5: 232-51.

  9. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-6.

  10. Bonacini M, Govindarajan S, Blatt L, Schmid P, Conrad A, Lindsay K. Patients coinfected with HIV and hepatitis C demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6: 203-8.

  11. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.

  12. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4+ cells depletion in patients with hepatitis C and HIV coinfection. J Infect Dis 2001; 183:134-7.

  13. Martínez-Sierra C, Arizcorreta A, Díaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2003; 36: 491-98.

  14. Martín-Cabonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C – a European collaborative study. Clin Infect Dis 2004; 38: 128-33.

  15. Eyster M, Diamondstone L, Lien J, et al. Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with HIV. A multicenter hemophilia cohort study. J Acquir Immun Defic Syndr 1993; 6: 602-10.

  16. Sanchez-Quijano A, Andreu J, Gavilan S, et al. Influence of HIV type 1 infection on the natural history of chronic parenteral acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-53.

  17. Rockstroh J, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563-8.

  18. Soto B, Sanchez-Quijano A, Rodrigo L et al. HIV infection modifies the natural history of chronic parenteral acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.

  19. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.

  20. Tedaldi E, Baker R, Moorman A, et al. Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART. Clin Infect Dis 2003; 36: 363-7.

  21. Dronda F, Zamora J, Moreno S, et al. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18: 2210-2.

  22. Nuñez M, Soriano V. Hepatotoxicity of antiretrovirals. Incidence, mechanisms and management. Drug Safety 2005; 28: 53-66.

  23. Bräu N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17: 2279-90.

  24. Rockstroh J, Spengler U. HIV/HCV coinfection. Lancet Infect Dis 2004; 4: 437-44.

  25. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. Update recommendations from the HIV-HCV International Panel. AIDS 2004; 18: 1-12.

  26. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.

  27. Sherman K, Roustrer S, Chung R, Rajicic N. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antiviral Ther 2000; 5 (Suppl 1): 64-5.

  28. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  29. Rockstroh J, Konopnicki D, Soriano V, et al. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2004 [abstract 799].

  30. Hagan H, Thiede H, Weiss N, Hopkins S, Duchin J, Alexander E. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-6.

  31. Ghosn J, Pierre-Francois S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004; 5: 303-6.

  32. Masur H, Kaplan J, Holmes K. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 435-78.

  33. Beld M, Penning M, van Putten M, et al. Low levels of HCV RNA in serum, plasma, and PBMCs of IDUs during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183-91.

  34. George S, Gebhardt J, Klinzman D, et al. Hepatitis C viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immun Def Syndr 2002; 31: 154-62.

  35. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon Alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.

  36. Chung R, Andersen J, Volberding P, et al. Peginterferon Alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.

  37. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004; 292: 2839-48.

  38. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-36.

  39. Soriano V, Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, González-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004; 20: 351-4.

  40. Graham C, Wells A, Liu T, et al. Relationships between HCV-specific immune responses and outcomes of treatment with interferon and ribavirin in HIV-HCV co-infection. 11th Conference on Retroviruses and Opportunistic Infections. February 2004. San Francisco, CA [abstract 111].

  41. Vrolijk J, Kwekkeboom J, Janssen H, et al. Pre-treatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. J Infect Dis 2003; 188: 1528-32.

  42. Strader D, Wright T, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.

  43. Wong J, Bennett W, Koff R, Pauker S. Pre-treatment evaluation of chronic hepatitis C. Risks, benefits, and costs. JAMA 1998; 280: 2088-93.

  44. Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology 2001; 34: 438-9.

  45. Andriulli A, Mangia A, Niro G, Caturelli E. To biopsy or not to biopsy. Hepatology 2001; 34: 438.

  46. Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36 (Suppl): 152-60.

  47. Soriano V, Martín-Carbonero L, García-Samaniego J. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003; 17: 751-3.

  48. Kuehne F, Bethe U, Freedberg K, Goldie S. Treatment for hepatitis C virus in HIV-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002; 162: 2545-56.

  49. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005; 5: 15-21.

  50. Myers R, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17: 721-5.

  51. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.

  52. Soriano V, García-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585-91.

  53. Gao B, Hong F, Radaeva S. Host factors and failure of interferon treatment in hepatitis C virus. Hepatology 2004; 39: 880-90.

  54. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.

  55. Lee S, Bain V, Peltekian K, et al. Peginterferon alfa-2a (40 kD) (PEGASYS®) plus ribavirin (COPEGUS®) in cirrhotic patients with chronic hepatitis C: results of a Canadian multicenter open-label expanded access program. J Hepatol 2005; 42(Suppl 2): 211 [abstract 576].

  56. Lim J, Imperial J. Safety and efficacy of antiviral therapy in patients with decompensated cirrhosis associated with chronic hepatitis C infection. J Hepatol 2005; 42(Suppl 2): 211 [abstract 579].

  57. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-23.

  58. Backmund M, Meyer K, von Zielonka V, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.

  59. Edlin B. Prevention and treatment of hepatitis C in injecting drug users. Hepatology 2002; 36(Suppl): 210-9.

  60. Fultz S, Justice A, Butt A, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of Veterans with HIV infection. Clin Infect Dis 2003; 36: 1039-46.

  61. Rauch A, Egger M, Reichen J, Furrer H, and the Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-á plus ribavirin. J Acquir Immune Defic Syndr 2005; 38: 238-240.

  62. Restrepo A, Johnson T, Widjaja D, et al. The rate of treatment of chronic hepatitis C in patients coinfected with HIV in an urban medical centre. J Viral Hepatitis 2005; 12: 86-90.

  63. Butt A, Wagener M, Shakil A, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepatitis 2005; 12: 81-85.

  64. Fried M, Shiffman M, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  65. Davis G, Albright J, Cook S, Rosenberg D. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.

  66. Torriani F, Ribeiro R, Gilbert T, et al. HCV and HIV dynamics during HC treatment in HIV/HCV coinfection. J Infect Dis 2003; 188: 1498-507.

  67. Ballesteros A, Franco S, Fuster D, et al. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18: 59-66.

  68. Moreno L, Quereda C, Morena A, et al. Pegylated interferon-a 2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.

  69. Soriano V, Nuñez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9: 505-9.

  70. Neumann A, Lam N, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-7.

  71. Pawlotsky J. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl): 65-73.

  72. Talal A, Shata M, Markatou M, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immun Defic Syndr 2004; 35: 103-13.

  73. Fried M. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(Suppl): 237-44.

  74. Manns M, McHutchison J, Gordon S, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

  75. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-55.

  76. Dieterich D. Treatment of hepatitis C and anemia in HIV-infected patients. J Infect Dis 2002; 185(Suppl 2): 128-37.

  77. Afdhal N, Dieterich D, Pockros P, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients. A prospective, double-blind randomized controlled study. Gastroenterology 2004; 126: 1302-11.

  78. Gish R, Arora S, Nelson D, Fernández H, Lamon K. Safety and efficacy of Viramidine in combination with pegylated interferon alpha-2a for treatment of hepatitis C in therapy-naive patients. J Hep 2004; 40(Suppl 1): 141-2 [Abstract 479].

  79. Pesce A, Taillan B, Rosenthal E. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1597.

  80. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-1.

  81. Moyle G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies. AIDS Rev 2001; 3: 150-6.

  82. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon therapy. AIDS 2004; 18:F21-5.

  83. Rendon A, Nuñez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients. J Acquir Immun Defic Syndr (in press).

  84. Zingman B, Morales H, Rodriguez F, et al. HCV evaluation and treatment can be improved by a multidisciplinary HIV/HCV co-infection program: results from the first year of a program co-located at an urban HIV primary care clinic. Gastroenterology 2005; 128(Suppl 2): A-726.

  85. Breilh D. Plasma target concentration of ribavirin in HCV/HIV-co-infected patients. 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, 2005. Boston, MA [abstract 928].

  86. Brouwer J, Nevens F, Bekkering F, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C: a Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689-95.

  87. Drusano G, Preston S. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-70.

  88. Planas R, Fuster D, González J, et al. Multicenter pilot study to assess the efficacy and safety of prolonging treatment with peginterferon alpha 2 a (Pegasys) and ribavirin (Copegus) in HIV and HCV coinfected patients without early virological response. Gastroenterology 2005; 128(Suppl 2): A-682.

  89. Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. J Hepatol 2005; 42(Suppl 2): 211 [abstract 93].

  90. Reesink H, Zeuzem S, Vliet A, et al. Initial results of a phase 1 B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Gastroenterology 2005; 128(Suppl 2): A-697.

  91. Bacon B, McHutchinson J, Gordon S, et al. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilonä), a novel TLR9 agonist: comparison in normal volunteers and HCV infected individuals. Gastroenterology 2005; 128(Suppl 2): A-696.

  92. Blatt L, Cheung E, Radhakrishnan R, Ibarra L, Faris-Young S. A phase 1, single-blind, dose-escalating study of the safety and pharmacokinetics of a single injection of pegylated interferon Alpha 1 in healthy volunteers. Gastroenterology 2005; 128(Suppl 2): A-713.




2020     |     www.medigraphic.com